Clinical Trial Update: Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating TQB2450 in combination with Anlotinib in advanced cholangiocarcinoma (Phase 1/2) with status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Cholangiocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN